Neasa Starr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Neasa Starr has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Emer Joyce
Department of Cardiology, Mater Misericordiae University Hospital, Eccles Street Dublin 7, Ireland; UCD School of Medicine, UCD Health Sciences Centre, University College Dublin, Belfield, Dublin 4, Ireland
2 shared publications - Carmel Halley
Department of Cardiovascular Medicine, St. Vincent's University Hospital , Dublin
1 shared publication - Dia A. Smiley
Amyloidosis Program, Nuclear Cardiology, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Florida, Weston, Florida
1 shared publication - Gerard Giblin
Department of Cardiology, Mater Misericordiae University Hospital, Dublin, Ireland
1 shared publication - Gerard Giblin
Department of Cardiology, Mater Misericordiae University Hospital, Dublin, Ireland
1 shared publication - Joseph Patrick Morris
Department of Cardiology, Mater Misericordiae University Hospital, Dublin, Ireland
1 shared publication
Latest Publications
- 12 May 2026
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 32 (5) , 935-938
“The Future Is Bright and Speckled” as We Explore Our Collective Experience Regarding Fellowships Completed in Subspecialty Cardiac Amyloidosis Centers
- 12 May 2026
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 32 (5) , 935-938
“The Future Is Bright and Speckled” as We Explore Our Collective Experience Regarding Fellowships Completed in Subspecialty Cardiac Amyloidosis Centers
- Open Access
- 11 November 2024
- Published by BMJ in Open Heart
- Vol. 11 (2) , e002906
Spectrum of hereditary transthyretin amyloidosis due to T60A(p.Thr80Ala) variant in an Irish Amyloidosis Network
Background: Variant transthyretin amyloidosis (ATTRv) is a hereditary multisystem disorder with clinical spectrum ranging from predominant cardiomyopathy to polyneuropathy. In the Irish population, the T60A mutation has been previously recognised as the most common genotype. Objectives: The aim of this study is to describe the diagnostic and phenotypic spectrum of patients with T60A ATTRv attending an Irish Expert Amyloidosis Network. Methods: In this observational study design, the medical, laboratory and radiological records of patients enrolled in our amyloidosis registry with a confirmed genotype diagnosis of T60A ATTRv were reviewed. Results: A cohort of 24 patients (12 female) met criteria for inclusion. The median age at diagnosis was 65 years (IQR 59.5–66.5) and median follow-up 44 months (IQR 31–58). Carpal tunnel syndrome was the initial manifestation in almost half (46%) of patients. Overall, a mixed cardioneuro phenotype was demonstrated including autonomic (75%), small (58%) and large fibre (46%) neuropathy largely predating a cardiac phenotype consisting of heart failure (63%), atrial arrhythmia (42%) and bradycardia (13%). Conclusion: The contemporary clinical spectrum of T60A ATTRv in Ireland is one of patients typically presenting in the seventh decade with an already manifest neuropathy phenotype, largely predating a cardiac phenotype dominated by heart failure.
- 11 November 2024
- Published by BMJ in Open Heart
- Vol. 11 (2) , e002906
Open AccessSpectrum of hereditary transthyretin amyloidosis due to T60A(p.Thr80Ala) variant in an Irish Amyloidosis Network
Background: Variant transthyretin amyloidosis (ATTRv) is a hereditary multisystem disorder with clinical spectrum ranging from predominant cardiomyopathy to polyneuropathy. In the Irish population, the T60A mutation has been previously recognised as the most common genotype. Objectives: The aim of this study is to describe the diagnostic and phenotypic spectrum of patients with T60A ATTRv attending an Irish Expert Amyloidosis Network. Methods: In this observational study design, the medical, laboratory and radiological records of patients enrolled in our amyloidosis registry with a confirmed genotype diagnosis of T60A ATTRv were reviewed. Results: A cohort of 24 patients (12 female) met criteria for inclusion. The median age at diagnosis was 65 years (IQR 59.5–66.5) and median follow-up 44 months (IQR 31–58). Carpal tunnel syndrome was the initial manifestation in almost half (46%) of patients. Overall, a mixed cardioneuro phenotype was demonstrated including autonomic (75%), small (58%) and large fibre (46%) neuropathy largely predating a cardiac phenotype consisting of heart failure (63%), atrial arrhythmia (42%) and bradycardia (13%). Conclusion: The contemporary clinical spectrum of T60A ATTRv in Ireland is one of patients typically presenting in the seventh decade with an already manifest neuropathy phenotype, largely predating a cardiac phenotype dominated by heart failure.
- Open Access
- 27 June 2022
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 9 (5) , 3643-3648
A Survey-Based Triage Tool to Identify Patients Potentially Eligible for Referral to an Advanced Heart Failure Centre
Aims: Accurate prevalence data for ambulatory advanced heart failure (HF) in European countries remains limited. This study was designed to identify the population of patients potentially eligible for referral for assessment for advanced surgical HF therapies to a National advanced HF and cardiac transplant centre. Methods and results: A survey comprising 13 potential clinical markers of advanced HF was developed, modified from the ‘I NEED HELP’ tool from the 2018 position statement of the Heart Failure Association of the European Society of Cardiology, and distributed to all HF clinic services (secondary and tertiary units) nationwide. Each HF clinic unit was asked to complete the survey on consecutive patients over a 3 month period fulfilling the following three criteria: (i) age <65 years; (ii) ejection fraction 3 months duration. As a comparison, the number of actual referrals to the advanced HF clinic were also audited over a 9 month period. In all, 21 of 26 HF clinic units participated in the survey. Across the period of inclusion, 4950 all-comer HF patients were seen across all sites. Of these, 375 (7.5%) fulfilled the inclusion criteria and were surveyed (74.4% male, median age 57 years [IQR: 11 years]). In total, 246 (66%) of the surveyed patients had ≥1 potential markers for advanced HF, representing just under 5% of the total all-comer HF population seen across the same time period. Of these, 67 patients (27%) had ≥2, 48 (20%) had 3 and 40 (16%) had ≥4 potential markers. The most frequently noted markers were ≥1 HF hospitalization or unscheduled clinic review (56%), intolerance to renin-angiotensin-aldosterone system inhibitors due to hypotension or renal dysfunction (29%) and intolerance to beta-blockers due to hypotension (27%). Almost one-quarter of patients reported NYHA Class III or IV symptoms. During the advanced HF clinic audit, the number of patients actually referred to the advanced HF clinic during the same time period was <5% of this potentially eligible cohort. Conclusions: In this index prospective National survey, approximately 5% of an all-comer routine HF clinic population and two-thirds of a pre-selected HF with reduced EF under 65 years cohort were found to have at least one clinical or biochemical marker suggesting advanced or impending advanced HF. Almost one-quarter of patients in this chronic outpatient ‘snapshot’ population have NYHA III-IV symptoms. This simple one-page triage survey—modified from the ‘I NEED HELP’ tool—is useful to identify a population potentially eligible for referral to an advanced HF centre for assessment for advanced surgical therapies, thereby aiding resource and service planning.
- 27 June 2022
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 9 (5) , 3643-3648
Open AccessA Survey-Based Triage Tool to Identify Patients Potentially Eligible for Referral to an Advanced Heart Failure Centre
Aims: Accurate prevalence data for ambulatory advanced heart failure (HF) in European countries remains limited. This study was designed to identify the population of patients potentially eligible for referral for assessment for advanced surgical HF therapies to a National advanced HF and cardiac transplant centre. Methods and results: A survey comprising 13 potential clinical markers of advanced HF was developed, modified from the ‘I NEED HELP’ tool from the 2018 position statement of the Heart Failure Association of the European Society of Cardiology, and distributed to all HF clinic services (secondary and tertiary units) nationwide. Each HF clinic unit was asked to complete the survey on consecutive patients over a 3 month period fulfilling the following three criteria: (i) age <65 years; (ii) ejection fraction 3 months duration. As a comparison, the number of actual referrals to the advanced HF clinic were also audited over a 9 month period. In all, 21 of 26 HF clinic units participated in the survey. Across the period of inclusion, 4950 all-comer HF patients were seen across all sites. Of these, 375 (7.5%) fulfilled the inclusion criteria and were surveyed (74.4% male, median age 57 years [IQR: 11 years]). In total, 246 (66%) of the surveyed patients had ≥1 potential markers for advanced HF, representing just under 5% of the total all-comer HF population seen across the same time period. Of these, 67 patients (27%) had ≥2, 48 (20%) had 3 and 40 (16%) had ≥4 potential markers. The most frequently noted markers were ≥1 HF hospitalization or unscheduled clinic review (56%), intolerance to renin-angiotensin-aldosterone system inhibitors due to hypotension or renal dysfunction (29%) and intolerance to beta-blockers due to hypotension (27%). Almost one-quarter of patients reported NYHA Class III or IV symptoms. During the advanced HF clinic audit, the number of patients actually referred to the advanced HF clinic during the same time period was <5% of this potentially eligible cohort. Conclusions: In this index prospective National survey, approximately 5% of an all-comer routine HF clinic population and two-thirds of a pre-selected HF with reduced EF under 65 years cohort were found to have at least one clinical or biochemical marker suggesting advanced or impending advanced HF. Almost one-quarter of patients in this chronic outpatient ‘snapshot’ population have NYHA III-IV symptoms. This simple one-page triage survey—modified from the ‘I NEED HELP’ tool—is useful to identify a population potentially eligible for referral to an advanced HF centre for assessment for advanced surgical therapies, thereby aiding resource and service planning.